{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:41:46Z","timestamp":1794876106930,"version":"4.9.1"},"reference-count":39,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2019,8,30]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Macrophage interleukin (IL)-10 signalling plays a critical role in the maintenance of a regulatory phenotype that prevents the development of IBD. We have previously found that anti-tumour necrosis factor (TNF) monoclonal antibodies act through Fc\u03b3-receptor (Fc\u03b3R) signalling to promote repolarisation of proinflammatory intestinal macrophages to a CD206+ regulatory phenotype. The role of IL-10 in anti-TNF-induced macrophage repolarisation has not been examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      We used human peripheral blood monocytes and mouse bone marrow-derived macrophages to study IL-10 production and CD206+ regulatory macrophage differentiation. To determine whether the efficacy of anti-TNF was dependent on IL-10 signalling in vivo and in which cell type, we used the CD4+CD45Rb\n                      <jats:sup>high<\/jats:sup>\n                      T-cell transfer model in combination with several genetic mouse models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Anti-TNF therapy increased macrophage IL-10 production in an Fc\u03b3R-dependent manner, which caused differentiation of macrophages to a more regulatory CD206+ phenotype in vitro. Pharmacological blockade of IL-10 signalling prevented the induction of these CD206+ regulatory macrophages and diminished the therapeutic efficacy of anti-TNF therapy in the CD4+CD45Rb\n                      <jats:sup>high<\/jats:sup>\n                      T-cell transfer model of IBD. Using cell type-specific IL-10 receptor mutant mice, we found that IL-10 signalling in macrophages but not T cells was critical for the induction of CD206+ regulatory macrophages and therapeutic response to anti-TNF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The therapeutic efficacy of anti-TNF in resolving intestinal inflammation is critically dependent on IL-10 signalling in macrophages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2019-318264","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T17:15:41Z","timestamp":1568135741000},"page":"1053-1063","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":233,"title":["Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling"],"prefix":"10.1136","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-9014","authenticated-orcid":false,"given":"Pim J","family":"Koelink","sequence":"first","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia M","family":"Bloemendaal","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Department of Gastroenterology and hepatology, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liset","family":"Westera","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W M","family":"Vogels","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"van Roest","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk K","family":"Gloudemans","sequence":"additional","affiliation":[{"name":"Janssen Prevention Center of Janssen Vaccines & Prevention BV, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique B","family":"van 't Wout","sequence":"additional","affiliation":[{"name":"Janssen Prevention Center of Janssen Vaccines & Prevention BV, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelie","family":"Korf","sequence":"additional","affiliation":[{"name":"Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anje A","family":"te Velde","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert RAM","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Sjef","family":"Verbeek","sequence":"additional","affiliation":[{"name":"Human Genetics, Leids Universitair Medisch Centrum, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence L","family":"Geiger","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon E","family":"Wildenberg","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Gastroenterology & Hepatology, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs R","family":"van den Brink","sequence":"additional","affiliation":[{"name":"Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Gastroenterology & Hepatology, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Roche Innovation Center Basel, F Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"2025112109174839000_69.6.1053.1","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to Anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2025112109174839000_69.6.1053.2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"ECCOJC"},{"key":"2025112109174839000_69.6.1053.3","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"2025112109174839000_69.6.1053.4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025112109174839000_69.6.1053.5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"2025112109174839000_69.6.1053.6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2025112109174839000_69.6.1053.8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng.221","article-title":"Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility","volume":"40","author":"Franke","year":"2008","journal-title":"Nat Genet"},{"key":"2025112109174839000_69.6.1053.9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-Wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci","volume":"42","author":"Franke","year":"2010","journal-title":"Nat Genet"},{"key":"2025112109174839000_69.6.1053.10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"K\u00fchn","year":"1993","journal-title":"Cell"},{"key":"2025112109174839000_69.6.1053.11","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med"},{"key":"2025112109174839000_69.6.1053.12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","article-title":"Macrophage-Restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis","volume":"40","author":"Zigmond","year":"2014","journal-title":"Immunity"},{"key":"2025112109174839000_69.6.1053.13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.immuni.2014.03.011","article-title":"Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function","volume":"40","author":"Shouval","year":"2014","journal-title":"Immunity"},{"key":"2025112109174839000_69.6.1053.14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jlb.61.4.389","article-title":"Studies with IL-10-\/- mice: an overview","volume":"61","author":"Rennick","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2025112109174839000_69.6.1053.15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ecco-jcc\/jjv179","article-title":"Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease","volume":"10","author":"McRae","year":"2016","journal-title":"ECCOJC"},{"key":"2025112109174839000_69.6.1053.16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/j.gastro.2017.07.021","article-title":"Anti-Tumor necrosis factor with a Glyco-Engineered Fc-Region has increased efficacy in mice with colitis","volume":"153","author":"Bloemendaal","year":"2017","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-Tumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2025112109174839000_69.6.1053.19","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.4049\/jimmunol.166.11.6861","article-title":"Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors","volume":"166","author":"Gerber","year":"2001","journal-title":"J Immunol"},{"key":"2025112109174839000_69.6.1053.20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.175.1.469","article-title":"ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus","volume":"175","author":"Lucas","year":"2005","journal-title":"J Immunol"},{"key":"2025112109174839000_69.6.1053.21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imlet.2010.07.004","article-title":"The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production","volume":"133","author":"Gallo","year":"2010","journal-title":"Immunol Lett"},{"key":"2025112109174839000_69.6.1053.22","doi-asserted-by":"crossref","unstructured":"Read S , Powrie F . Induction of inflammatory bowel disease in immunodeficient mice by depletion of regulatory T cells. Curr Protoc Immunol 2001;Chapter 15.doi:10.1002\/0471142735.im1513s30","DOI":"10.1002\/0471142735.im1513s30"},{"key":"2025112109174839000_69.6.1053.23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ecco-jcc\/jjx104","article-title":"Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model","volume":"11","author":"Wildenberg","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025112109174839000_69.6.1053.24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ecco-jcc\/jjy035","article-title":"Development of reliable, valid and responsive scoring systems for endoscopy and histology in animal models for inflammatory bowel disease","volume":"12","author":"Koelink","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025112109174839000_69.6.1053.25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/107999099313695","article-title":"The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes","volume":"19","author":"Donnelly","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"2025112109174839000_69.6.1053.26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7131","article-title":"Il-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"2025112109174839000_69.6.1053.27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2012.04.045","article-title":"Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy","volume":"143","author":"Kotlarz","year":"2012","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2249.1997.291-ce1184.x","article-title":"Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice","volume":"107","author":"Kojouharoff","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2025112109174839000_69.6.1053.29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1084\/jem.20090849","article-title":"TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis","volume":"207","author":"Noti","year":"2010","journal-title":"J Exp Med"},{"key":"2025112109174839000_69.6.1053.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041797","article-title":"A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features","volume":"7","author":"Hale","year":"2012","journal-title":"PLoS One"},{"key":"2025112109174839000_69.6.1053.31","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/eji.200839132","article-title":"Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis","volume":"39","author":"Dayer Schneider","year":"2009","journal-title":"Eur J Immunol"},{"key":"2025112109174839000_69.6.1053.32","doi-asserted-by":"crossref","unstructured":"Bloemendaal FM , Koelink PJ , van Schie KA , et al . TNF-anti-TNF immune complexes inhibit IL-12\/IL-23 secretion by inflammatory macrophages via an Fc-dependent mechanism. J Crohns Colitis 2018;10.doi:10.1093\/ecco-jcc\/jjy075","DOI":"10.1093\/ecco-jcc\/jjy075"},{"key":"2025112109174839000_69.6.1053.33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MIB.0b013e3182917a2b","article-title":"Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease","volume":"19","author":"Verhaar","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2025112109174839000_69.6.1053.34","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14\u207a macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/gutjnl-2012-302262","article-title":"Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol","volume":"62","author":"H\u00e9buterne","year":"2013","journal-title":"Gut"},{"key":"2025112109174839000_69.6.1053.36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"2025112109174839000_69.6.1053.37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the extend trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"2025112109174839000_69.6.1053.38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/MPG.0000000000001795","article-title":"Impaired IL-10 receptor-mediated suppression in monocyte from patients with Crohn disease","volume":"66","author":"Nunberg","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025112109174839000_69.6.1053.39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2016.08.055","article-title":"Interleukin 1\u03b2 mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency","volume":"151","author":"Shouval","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-318264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:18:00Z","timestamp":1763745480000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-318264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/gutjnl-2019-318264"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-318264","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736587115.793572758","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}